NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Testicular Cancer

Version 2.2015

NCCN.org
**NCCN Guidelines Version 2.2015 Panel Members**

**Testicular Cancer**

<table>
<thead>
<tr>
<th>Member Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert J. Motzer, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Eric Jonasch, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Neeraj Agarwal, MD</td>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td>Clair Beard, MD</td>
<td>Dana-Farber/Brigham and Women's Cancer Center</td>
</tr>
<tr>
<td>Sam Bhayani, MD</td>
<td>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</td>
</tr>
<tr>
<td>Graeme B. Bolger, MD</td>
<td>University of Alabama at Birmingham Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Sam S. Chang, MD</td>
<td>Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td>Toni K. Choueiri, MD</td>
<td>Dana-Farber/Brigham and Women's Cancer Center</td>
</tr>
<tr>
<td>Brian A. Costello, MD</td>
<td>Mayo Clinic Cancer Center</td>
</tr>
<tr>
<td>Ithaar H. Derweesh, MD</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Shilpa Gupta, MD</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>Steven L. Hancock, MD</td>
<td>Stanford Cancer Institute</td>
</tr>
<tr>
<td>Jenny J. Kim, MD</td>
<td>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
</tr>
<tr>
<td>Timothy M. Kuzel, MD</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td>Elaine T. Lam, MD</td>
<td>University of Colorado Cancer Center</td>
</tr>
<tr>
<td>Clayton Lau, MD</td>
<td>City of Hope Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Ellis G. Levine, MD</td>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td>Daniel W. Lin, MD</td>
<td>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</td>
</tr>
<tr>
<td>M. Dror Michaelson, MD, PhD</td>
<td>Massachusetts General Hospital Cancer Center</td>
</tr>
<tr>
<td>Thomas Olencki, DO</td>
<td>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute</td>
</tr>
<tr>
<td>Roberto Pili, MD</td>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td>Elizabeth R. Plimack, MD, MS</td>
<td>Fox Chase Cancer Center</td>
</tr>
<tr>
<td>Edward N. Rampersaud, MD</td>
<td>Duke Cancer Institute</td>
</tr>
<tr>
<td>Bruce G. Redman, DO</td>
<td>University of Michigan Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Charles J. Ryan, MD</td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Joel Sheinfeld, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Brian Shuch, MD</td>
<td>Yale Cancer Center/Smilow Cancer Hospital</td>
</tr>
<tr>
<td>Kanishka Sirca, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Brad Somer, MD</td>
<td>St. Jude Children's Research Hospital/University of Tennessee Health Science Center</td>
</tr>
<tr>
<td>Richard B. Wilder, MD</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>Mary Dwyer, MS</td>
<td>NCCN</td>
</tr>
<tr>
<td>Rashmi Kumar, PhD</td>
<td>NCCN</td>
</tr>
<tr>
<td>Sarika Trikha, PharmD</td>
<td>NCCN</td>
</tr>
</tbody>
</table>

NCCN Guidelines Panel Disclosures
Workup, Primary Treatment, and Pathologic Diagnosis (TEST-1)

Pure Seminoma: Postdiagnostic Workup and Clinical Stage (TEST-2)
- Stage IA, IB (TEST-3)
- Stage IS (TEST-3)
- Stage IIA, IIB (TEST-4)
- Stage IIC, III (TEST-4)

Nonseminoma: Postdiagnostic Workup and Clinical Stage (TEST-6)
- Stage IA, IB, IS (TEST-7)
- Stage IIA, IIB (TEST-8)
- Postchemotherapy Management (TEST-9)
- Postsurgical Management (TEST-10)
- Stage IS, IIA S1, IIB S1, IIC, IIIA, IIB, IIIC, and Brain Metastases (TEST-11)

Recurrence and Second-Line Therapy (TEST-12)

Follow-up for Seminoma (TEST-A)
Follow-up for Nonseminoma (TEST-B)
Principles of Radiotherapy for Pure Testicular Seminoma (TEST-C)
Risk Classification for Advanced Disease (TEST-D)
Primary Chemotherapy Regimens for Germ Cell Tumors (TEST-E)
Second-Line Chemotherapy Regimens for Metastatic Germ Cell Tumors (TEST-F)
Subsequent Chemotherapy Regimens for Metastatic Germ Cell Tumors (TEST-G)
Principles of Surgery for Germ-Cell Tumors (TEST-H)

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2015.

Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See NCCN Categories of Evidence and Consensus.
Updates in Version 2.2015 of the NCCN Guidelines for Testicular Cancer from Version 1.2015 include:

**MS-1**
- The Discussion section was updated to reflect the changes in the algorithm.

Updates in Version 1.2015 of the NCCN Guidelines for Testicular Cancer from Version 1.2014 include:

**New to the Guidelines**
- Follow-up
  - The follow-up recommendations for both pure seminoma (**TEST-A**) and nonseminomatous germ cell tumor (NSGCT) (**TEST-B**) were extensively revised. For seminoma, the recommendation was removed from the algorithms and placed in tables.

**Seminoma**

**TEST-3**
- Stage IA, IB
  - Primary treatment
    - For single-agent carboplatin, the category was changed from a 1 to a 2A.
    - The dose for RT was added, “20 Gy,” and the category was changed from a 1 to a 2A.
  - The follow-up recommendations were removed from page and directed to new “Follow-up for Seminoma” section.

**TEST-4**
- For Stage IIA
  - Primary treatment, the RT recommendation was revised, “RT to include para-aortic and ipsilateral iliac lymph nodes to a dose of 30 to 36 Gy (preferred).”
- For Stage IIB
  - Primary treatment, the RT recommendation was revised, “RT in select non-bulky cases to include para-aortic and ipsilateral iliac lymph nodes to a dose of 30 to 36 Gy.”
  - The follow-up recommendations after RT were removed from the page and directed to new “Follow-up for Seminoma” section.

**TEST-5**
- Post chemotherapy follow-up recommendations were removed from the page and directed to new “Follow-up for Seminoma” section.
Updates in Version 1.2015 of the NCCN Guidelines for Testicular Cancer from Version 1.2014 include:

**Nonseminoma**
- Follow-up for nonseminoma links to corresponding tables were added throughout the section.

**TEST-9**
- Stage IB was removed from the postchemotherapy management page.
- Stage IIA, IIB treated with primary chemotherapy
  - Postchemotherapy management for negative markers, no mass, or residual mass <1 cm on CT scan:
    - Surveillance was changed from a category 2B to a 2A.
    - Nerve-sparing bilateral RPLND was modified by adding, “in selected cases.”

**TEST-11**
- Post-chemotherapy management
  - For a complete response, negative markers,
    - If original stage was Stage IS, the surveillance recommendation was changed from category 2B to a 2A.
    - If original stage was Stage IIA, S1; Stage IIB, S1; Stage IIC; or Stage IIIA, “Surveillance” was changed from a category 2B to a 2A and “Bilateral RPLND ± nerve-sparing” was modified by adding, “in selected cases.”

**TEST-12**
- Second-line therapy
  - For unfavorable prognosis and late relapse, after second-line therapy, the decision points “complete response” and “incomplete response or persistent disease” with corresponding treatment options replaced “persistent disease or relapse.”

**Testicular Cancer**

**TEST-C 3 of 5**
- For Stage IIA/B, the modified dog-leg field dose was revised, “Dose: The initial phase consists of treatment of modified dog-leg fields to 20.0 Gy (midplane) in 10 daily 2.0–Gy fractions or 25.5 Gy in 15 daily 1.7–Gy fractions.”
**WORKUP**

<table>
<thead>
<tr>
<th>Suspicious testicular mass</th>
</tr>
</thead>
<tbody>
<tr>
<td>• H&amp;P</td>
</tr>
<tr>
<td>• Alpha-fetoprotein (AFP)</td>
</tr>
<tr>
<td>• beta-hCG(^a)</td>
</tr>
<tr>
<td>• LDH</td>
</tr>
<tr>
<td>• Chemistry profile</td>
</tr>
<tr>
<td>• Chest x-ray</td>
</tr>
<tr>
<td>• Testicular ultrasound</td>
</tr>
</tbody>
</table>

**PRIMARY TREATMENT\(^b\)**

- Discuss sperm banking
- Radical inguinal orchiectomy
- Consider inguinal biopsy of contralateral testis if:
  - Suspicious ultrasound for intratesticular abnormalities
  - Cryptorchid testis
  - Marked atrophy

**PATHOLOGIC DIAGNOSIS**

- Pure seminoma (pure seminoma histology and AFP negative; may have elevated beta-hCG)
- Nonseminomatous germ cell tumor (NSGCT) (includes mixed seminoma/nonseminoma tumors and seminoma histology with elevated AFP)

\(^a\)Quantitative analysis of beta subunit.

\(^b\)Though rare, when a patient presents with rapidly increasing beta-hCG and symptoms related to disseminated disease and a testicular mass, chemotherapy can be initiated immediately without waiting for a biopsy diagnosis.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Pure seminoma\(^c\)
(pure seminoma histology and AFP negative;\(^d\) may have elevated beta-hCG)

- Abdominal/pelvic CT
- Chest CT if:
  - Positive abdominal CT or abnormal chest x-ray
- Repeat beta-hCG, LDH, AFP since TNM staging is based on post-orchiectomy values\(^e\)
- Brain MRI, if clinically indicated
- Bone scan, if clinically indicated
- Discuss sperm banking

### Clinical Stage\(^e\)

- **Stage IA, IB**
  - See Primary Treatment and Follow-up (TEST-3)
- **Stage IS**
- **Stage IIA, IIB**
  - See Primary Treatment and Follow-up (TEST-4)
- **Stage IIC, III**

---

\(^c\)Mediastinal primary seminoma should be treated by risk status used for gonadal seminomas with etoposide/cisplatin for 4 cycles or bleomycin/etoposide/cisplatin for 3 cycles.

\(^d\)If AFP positive, treat as nonseminoma.

\(^e\)Elevated values should be followed after orchiectomy with repeated determination to allow precise staging.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## NCCN Guidelines Version 2.2015

### Testicular Cancer - Pure Seminoma

#### Clinical Stage

<table>
<thead>
<tr>
<th>Stage</th>
<th>Primary Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA, IB</td>
<td>Surveillance for pT1-pT3 tumors (category 1) (preferred)</td>
<td>See Follow-up for Seminoma, Table 1 (TEST-A 1 of 2)</td>
</tr>
<tr>
<td></td>
<td>or Single-agent carboplatin (AUC=7 x 1 cycle or AUC=7 x 2 cycles)</td>
<td>See Follow-up for Seminoma, Table 2 (TEST-A 1 of 2)</td>
</tr>
<tr>
<td></td>
<td>or RT (20 Gy)</td>
<td>See Follow-up for Seminoma, Table 2 (TEST-A 1 of 2)</td>
</tr>
</tbody>
</table>

- **Stage IS**
  - Repeat elevated serum tumor marker and assess with abdominal/pelvic CT scan for evaluable disease
  - Recurrence, treat according to extent of disease at relapse

---

**g**See Principles of Radiotherapy for Pure Testicular Seminoma (TEST-C).

**h**For Stage IS, see Discussion.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## Testicular Cancer - Pure Seminoma

### CLINICAL STAGE

#### Stage IIA
- **PRIMARY TREATMENT**
  - RT to include para-aortic and ipsilateral iliac lymph nodes to a dose of 30 Gy$^f$(preferred) or
  - Primary chemotherapy:$^k$
    - EP for 4 cycles or BEP for 3 cycles for multiple positive lymph nodes

#### Stage IIB
- **PRIMARY TREATMENT**
  - Primary chemotherapy (preferred):$^k$
    - EP for 4 cycles or BEP for 3 cycles or
  - RT in select non-bulky cases to include para-aortic and ipsilateral iliac lymph nodes to a dose of 36 Gy$^f$

#### Stage IIC, III
- **PRIMARY TREATMENT**
  - Good risk:$^j$
    - Primary chemotherapy:$^k$
      - EP for 4 cycles (category 1) or
      - BEP for 3 cycles (category 1)
  - Intermediate risk:$^j$
    - Primary chemotherapy:$^k$
      - BEP for 4 cycles (category 1)

### FOLLOW-UP

- See Follow-up for Seminoma, Table 3 (TEST-A 2 of 2)
- Recurrence, treat according to extent of disease at relapse

---

$^f$See Principles of Radiotherapy for Pure Testicular Seminoma (TEST-C).

$^i$All stage IIC and stage III seminoma is considered good-risk disease except for stage III disease with non-pulmonary visceral metastases (eg, bone, liver, or brain), which is considered intermediate risk.

$^j$See Risk Classification for Advanced Disease (TEST-D).

$^k$See Primary Chemotherapy Regimens for Germ Cell Tumors (TEST-E).

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**EP = Etoposide/cisplatin**

**BEP = Bleomycin/etoposide/cisplatin**

---

Version 2.2015, 05/04/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
**STAGE IIA, IIB, IIC, III AFTER PRIMARY TREATMENT WITH CHEMOTHERAPY**

- Chest, abdominal, pelvic CT scan
- Serum tumor markers

<table>
<thead>
<tr>
<th>Post-Chemotherapy Management</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Post-Chemotherapy Management</strong></td>
<td></td>
</tr>
<tr>
<td>No residual mass or residual mass ≤3 cm and normal markers</td>
<td>Surveillance</td>
</tr>
<tr>
<td>Residual mass (&gt;3 cm) and normal markers</td>
<td>PET scan (6 wks or more post-chemotherapy)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>Surveillance</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
</tr>
<tr>
<td></td>
<td>Consider RPLND, if technically feasible¹ or Second-line chemotherapyᵐ</td>
</tr>
<tr>
<td>Progressive disease (growing mass or rising markers)</td>
<td>See Second-Line Therapy for Nonseminoma (TEST-12)</td>
</tr>
</tbody>
</table>

¹If viable seminoma found by retroperitoneal lymph node dissection (RPLND), see TEST-11 (residual embryonal, yolk sac, choriocarcinoma, or seminoma elements).


**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### NCCN Guidelines Version 2.2015
**Testicular Cancer - Nonseminoma**

#### PATHOLOGIC DIAGNOSIS

- NSGCT (includes mixed seminoma/nonseminoma tumors and seminoma histology with elevated AFP)

#### POSTDIAGNOSTIC WORKUP

- Abdominal/pelvic CT ± chest imaging
- Repeat beta-hCG, LDH, AFP since TNM staging is based on post-orchiectomy values
- Brain MRI, if clinically indicated
- Bone scan, if clinically indicated
- Discuss sperm banking

#### CLINICAL STAGE

- **Stage IA, IB, IS**
  - See Primary Treatment (TEST-7)

- **Stage IIA, IIB**
  - See Primary Treatment (TEST-8)

- **Stage IIC, IIIA, IIIB, IIIC, and brain metastasis**
  - See Primary Treatment (TEST-11)

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

© National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
### Clinical Stage

<table>
<thead>
<tr>
<th>Stage</th>
<th>PRIMARY TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>Surveillance (preferred) → See Follow-up for Nonseminoma, Table 5 (TEST-B 1 of 3) or Nerve-sparing RPLND&lt;sup&gt;o,p&lt;/sup&gt; → See Postsurgical Management (TEST-10)</td>
</tr>
<tr>
<td>IB</td>
<td>Primary chemotherapy:&lt;sup&gt;k&lt;/sup&gt; BEP for 1–2 cycles → See Follow-up for Nonseminoma, Table 7 (TEST-B 2 of 3) or Surveillance for T2 only (category 2B) → See Follow-up for Nonseminoma, Table 6 (TEST-B 1 of 3)</td>
</tr>
<tr>
<td>IS</td>
<td>Persistent marker elevation → See Primary Treatment (TEST-11)</td>
</tr>
</tbody>
</table>

<sup>k</sup>See Primary Chemotherapy Regimens for Germ Cell Tumors (TEST-E).

<sup>o</sup>Retroperitoneal lymph node dissection (RPLND) is recommended within 4 weeks of CT scan and 7–10 days of markers.

<sup>p</sup>See Principles of Surgery for Germ Cell Tumors (TEST-H).

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**NCCN Guidelines Version 2.2015**

**Testicular Cancer - Nonseminoma**

Version 2.2015, 05/04/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
**NCCN Guidelines Version 2.2015**

**Testicular Cancer - Nonseminoma**

**CLINICAL STAGE**

- **Stage IIA**
  - Markers negative
    - Persistent marker elevation
      - Nerve-sparing RPLND<sup>0,p</sup>
      - or
      - Primary chemotherapy<sup>k</sup> (category 2B):
        - EP for 4 cycles or BEP for 3 cycles
      - See Primary Treatment (TEST-11)

- **Stage IIB**
  - Markers negative
    - Persistent marker elevation
      - Lymph node metastases, within lymphatic drainage sites
        - Primary chemotherapy<sup>k</sup>
          - EP for 4 cycles or BEP for 3 cycles
        - or
          - Nerve-sparing RPLND<sup>0,p</sup> in highly selected cases
      - See Primary Treatment (TEST-11)

- Multifocal, symptomatic, or lymph node metastases with aberrant lymphatic drainage
  - Primary chemotherapy<sup>k</sup>
    - EP for 4 cycles or BEP for 3 cycles
  - See Primary Treatment (TEST-11)

**PRIMARY TREATMENT**

- Nerve-sparing RPLND<sup>0,p</sup>
- or
- Primary chemotherapy<sup>k</sup> (category 2B):
  - EP for 4 cycles or BEP for 3 cycles
- See Postsurgical Management (TEST-10)

**PRINCIPLES**

- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Definitions**

- EP = Etoposide/cisplatin
- BEP = Bleomycin/etoposide/cisplatin

---

<sup>k</sup>See Primary Chemotherapy Regimens for Germ Cell Tumors (TEST-E).

<sup>0</sup>Retroperitoneal lymph node dissection (RPLND) is recommended within 4 weeks of CT scan and 7–10 days of markers.

<sup>p</sup>See Principles of Surgery for Germ Cell Tumors (TEST-H).
Stage IIA, IIB treated with primary chemotherapy

**POSTCHEMOTHERAPY MANAGEMENT**

- **Negative markers, residual mass (≥1 cm) on CT scan**
  - Nerve-sparing bilateral RPLND
  - See Follow-up for Nonseminoma, Table 8 (TEST-B 2 of 3)

- **Negative markers, no mass, or residual mass <1 cm on CT scan**
  - Surveillance
  - Nerve-sparing bilateral RPLND in selected cases (category 2B)
  - See Follow-up for Nonseminoma, Table 8 (TEST-B 2 of 3)

---

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

©Retroperitoneal lymph node dissection (RPLND) is recommended within 4 weeks of CT scan and 7–10 days of markers.

See Principles of Surgery for Germ Cell Tumors (TEST-H).
Stage IA, IB, IIA, IIB treated with primary nerve-sparing RPLND

pN0 → Surveillance → See Follow-up for Nonseminoma, Table 9 (TEST-B 3 of 3)

pN1 → Surveillance (preferred) or Chemotherapy: \( ^k \)

EP for 2 cycles or BEP for 2 cycles → See Follow-up for Nonseminoma, Table 9 (TEST-B 3 of 3)

pN2 → Chemotherapy: \( ^k \)

EP for 2 cycles or BEP for 2 cycles or Surveillance → See Follow-up for Nonseminoma, Table 9 (TEST-B 3 of 3)

pN3 → Chemotherapy: \( ^k \)

EP for 4 cycles or BEP for 3 cycles → See Follow-up for Nonseminoma, Table 9 (TEST-B 3 of 3)

EP = Etoposide/cisplatin
BEP = Bleomycin/etoposide/cisplatin

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### NCCN Guidelines Version 2.2015
#### Testicular Cancer - Nonseminoma

**CLINICAL STAGE**

<table>
<thead>
<tr>
<th>Stage</th>
<th>PRIMARY TREATMENT</th>
<th>POST-CHEMOTHERAPY MANAGEMENT</th>
</tr>
</thead>
</table>
| **Good risk**<sup>j</sup>  
Stage IS  
Stage IIA, S1  
Stage IIB, S1  
Stage IIC  
Stage IIIA | Primary chemotherapy<sup>k</sup>  
EP for 4 cycles (category 1)  
or  
BEP for 3 cycles (category 1) | If original stage, Stage IS  
Complete response, negative markers  
→ Surveillance |

| Stage IIIB | Primary chemotherapy<sup>k</sup>  
BEP for 4 cycles (category 1) | Partial response, residual masses<sup>s</sup>  
with normal AFP and beta-hCG levels  
→ Surgical resection of all residual masses  
Teratoma or necrosis  
→ Surveillance |

| Stage IIIC | Primary chemotherapy<sup>k</sup>  
BEP for 4 cycles (category 1)  
or  
VIP for 4 cycles in selected patients<sup>r</sup> (category 1) | Incomplete response<sup>s</sup>  
→ See Second-Line Therapy (TEST-12) |

**Intermediate risk**<sup>j</sup>  
Stage IIIB

| Poor risk<sup>j</sup>  
Stage IIIC | Primary chemotherapy<sup>k</sup>  
EP for 4 cycles (category 1)  
or  
BEP for 3 cycles (category 1)  
or  
VIP for 4 cycles in selected patients<sup>r</sup> (category 1) | Complete response, negative markers  
→ Surveillance |

**Brain metastases**<sup>q</sup>  
Primary chemotherapy<sup>k</sup> ± RT  
± surgery, if clinically indicated

---

<sup>j</sup>See Risk Classification for Advanced Disease (TEST-D).  
<sup>k</sup>See Primary Chemotherapy Regimens for Germ Cell Tumors (TEST-E).  
<sup>l</sup>See Second-Line Chemotherapy Regimens for Metastatic Germ Cell Tumors (TEST-F).

---

Note: All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

©NCCN, 2015. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
**NCCN Guidelines Version 2.2015**

**Testicular Cancer - Nonseminoma**

**Second-Line Therapy**

**RECURRENCE**

1. **Favorable prognosis:**
   - Low markers
   - Low volume
   - Complete response on first-line therapy
   - Testis primary

   - **Chemotherapy**
     - Conventional-dose therapy (VeIP or TIP)
     - High-dose chemotherapy

2. **Unfavorable prognosis:**
   - Incomplete response
   - High markers
   - High volume
   - Extratesticular primary

   - **Chemotherapy**
     - Clinical trial (preferred) or
     - Conventional-dose therapy (VeIP or TIP)
     - High-dose chemotherapy (category 2B)
     - Surgical salvage should be considered if solitary site

3. **Late relapse** (recurrence >2 years after completion of primary treatment)
   - Surgical salvage, if resectable (preferred)
   - **Chemotherapy**
     - Conventional-dose therapy (VeIP or TIP)
     - High-dose chemotherapy

4. **No prior chemotherapy**
   - Treat per risk status on **TEST-11**
   - Discuss sperm banking

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Examples of systems used to estimate prognosis are:**


**w**Includes best supportive care.

**See Subsequent Chemotherapy Regimens for Metastatic Germ Cell Tumors (TEST-G).**
FOLLOW-UP FOR SEMINOMA

The follow-up for seminoma tables are to provide guidance, and should be modified for the individual patient based upon sites of disease, biology of disease, and length of time on treatment. Reassessment of disease activity should be performed in patients with new or worsening signs or symptoms of disease, regardless of the time interval from previous studies.

Table 1  Clinical Stage I Seminoma: Surveillance after Orchiectomy

<table>
<thead>
<tr>
<th></th>
<th>Year (at month intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>H&amp;P&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Every 3–6 mo</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT</td>
<td>At 3, 6, and 12 mo</td>
</tr>
<tr>
<td>Chest x-ray</td>
<td>As clinically indicated, consider chest CT in symptomatic patients.</td>
</tr>
</tbody>
</table>

If Recurrence, treat according to extent of disease at relapse

Table 2  Clinical Stage I Seminoma: Surveillance after Adjuvant Treatment (Chemotherapy or Radiation)

<table>
<thead>
<tr>
<th></th>
<th>Year (at month intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>H&amp;P&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Every 6–12 mo</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT</td>
<td>Annually</td>
</tr>
<tr>
<td>Chest x-ray</td>
<td>As clinically indicated, consider chest CT in symptomatic patients.</td>
</tr>
</tbody>
</table>

If Recurrence, treat according to extent of disease at relapse

<sup>1</sup>Serum tumor markers are optional.
<sup>2</sup>Testicular ultrasound for any equivocal exam.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
# FOLLOW-UP FOR SEMINOMA

**Table 3 Clinical Stage IIA and Non-Bulky IIB Seminoma: Surveillance after Radiotherapy**

<table>
<thead>
<tr>
<th>Year (at month intervals)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;P&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Every 3 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT</td>
<td>At 3 mo, then at 6–12 mo</td>
<td>Annually</td>
<td>Annually</td>
<td>As clinically indicated</td>
<td></td>
</tr>
<tr>
<td>Chest x-ray&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
<td>----</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If Recurrence, treat according to extent of disease at relapse

**Table 4 Bulky Clinical Stage IIB and Stage III Seminoma: Surveillance Post-Chemotherapy with No Residual Mass or Residual Mass \(\leq 3\) cm and Normal Tumor Markers**

<table>
<thead>
<tr>
<th>Year (at month intervals)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;P and markers&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Every 2 mo</td>
<td>Every 3 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT&lt;sup&gt;4&lt;/sup&gt;</td>
<td>• Abdominal/pelvic CT at 3–6 months, then as clinically indicated • PET scan as clinically indicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest x-ray&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Every 2 mo&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Every 3 mo&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Annually</td>
<td>Annually</td>
<td>Annually</td>
</tr>
</tbody>
</table>

If Recurrence, see TEST-12.

---

<sup>1</sup>Serum tumor markers optional.

<sup>2</sup>Testicular ultrasound for any equivocal exam.

<sup>3</sup>Chest x-ray may be used for routine follow-up but chest CT is preferred in the presence of thoracic symptoms.

<sup>4</sup>Patients with PET-negative residual mass measuring >3 cm following chemotherapy should undergo an abdominopelvic CT scan every 6 months for the first year then annually for five years.

<sup>5</sup>Add chest CT if supradiaphragmatic disease present at diagnosis.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### FOLLOW-UP FOR NONSEMINOMA

The follow-up tables for nonseminoma are to provide guidance, and should be modified for the individual patient based upon sites of disease, biology of disease, and length of time on treatment. Reassessment of disease activity should be performed in patients with new or worsening signs or symptoms of disease, regardless of the time interval from previous studies.

#### Table 5  Clinical Stage IA, NSGCT: Active Surveillance

<table>
<thead>
<tr>
<th>Year (at month intervals)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;P and markers¹</td>
<td>Every 2 mo</td>
<td>Every 3 mo</td>
<td>Every 4–6 mo</td>
<td>Every 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT</td>
<td>Every 4–6 mo</td>
<td>Every 6–12 mo</td>
<td>Annually</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Chest x-ray²</td>
<td>At mo 4 and 12</td>
<td>Annually</td>
<td>Annually</td>
<td>Annually</td>
<td>Annually</td>
</tr>
</tbody>
</table>

If Recurrence, see TEST-12.

#### Table 6  Clinical Stage IB, NSGCT: Active Surveillance

<table>
<thead>
<tr>
<th>Year (at month intervals)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;P and markers¹</td>
<td>Every 2 mo</td>
<td>Every 3 mo</td>
<td>Every 4–6 mo</td>
<td>Every 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT</td>
<td>Every 4 mo</td>
<td>Every 4–6 mo</td>
<td>Every 6 mo</td>
<td>Annually</td>
<td>---</td>
</tr>
<tr>
<td>Chest x-ray²</td>
<td>Every 2 mo</td>
<td>Every 3 mo</td>
<td>Every 4–6 mo</td>
<td>Every 6 mo</td>
<td>Annually</td>
</tr>
</tbody>
</table>

If Recurrence, see TEST-12.

¹Testicular ultrasound for any equivocal exam.
²Chest x-ray may be used for routine follow-up but chest CT is preferred in the presence of thoracic symptoms.
### FOLLOW-UP FOR NONSEMINOMA

#### Table 7  Clinical Stage IB NSGCT: Treated with 1–2 Cycles of Adjuvant BEP Chemotherapy

<table>
<thead>
<tr>
<th></th>
<th>Year (at month intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>H&amp;P and markers(^1)</td>
<td>Every 3 mo</td>
</tr>
<tr>
<td>Abdominal/ Pelvic CT</td>
<td>Annually</td>
</tr>
<tr>
<td>Chest x-ray(^2)</td>
<td>Every 6–12 mo</td>
</tr>
</tbody>
</table>

If Recurrence, see TEST-12.

#### Table 8  Clinical Stage II-III NSGCT: Surveillance After Complete Response to Chemotherapy ± Post-chemotherapy RPLND

<table>
<thead>
<tr>
<th></th>
<th>Year (at month intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>H&amp;P and marker(^1)</td>
<td>Every 2 mo</td>
</tr>
<tr>
<td>Abdominal/ Pelvic CT(^3)</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td>Chest x-ray(^2,4)</td>
<td>Every 6 mo</td>
</tr>
</tbody>
</table>

If Recurrence, see TEST-12.

---

\(^1\)Testicular ultrasound for any equivocal exam.

\(^2\)Chest x-ray may be used for routine follow-up but chest CT is preferred in the presence of thoracic symptoms.

\(^3\)Patients who undergo RPLND and are found to have pN0 disease (no tumor or teratoma) need only 1 CT scan at postoperative month 4.

\(^4\)Chest CT if supradiaphragmatic disease at baseline.

\(^5\)Chest x-ray is optional at month 36 and 48.

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
FOLLOW-UP FOR NONSEMINOMA

Table 9  Pathologic Stage IIA/B NSGCT: Post-Primary RPLND and Treated with Adjuvant Chemotherapy

<table>
<thead>
<tr>
<th>Year (at month intervals)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;P and markers¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
<td>Annually</td>
<td>Annually</td>
<td>Annually</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After RPLND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest x-ray²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Every 6 mo</td>
<td>Annually</td>
<td>Annually</td>
<td>Annually</td>
<td>Annually</td>
</tr>
</tbody>
</table>

If Recurrence, see TEST-12.

Table 10  Pathologic Stage IIA/B NSGCT: Post-Primary RPLND and NOT Treated with Adjuvant Chemotherapy⁶

<table>
<thead>
<tr>
<th>Year (at month intervals)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;P and markers¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Every 2 mo</td>
<td>Every 3 mo</td>
<td>Every 4 mo</td>
<td>Every 6 mo</td>
<td>Annually</td>
</tr>
<tr>
<td>Abdominal/Pelvic CT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 3–4 mo⁷</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest x-ray²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Every 2–4 mo</td>
<td>Every 3–6 mo</td>
<td>Annually</td>
<td>Annually</td>
<td>Annually</td>
</tr>
</tbody>
</table>

If Recurrence, see TEST-12.

¹Testicular ultrasound for any equivocal exam.
²Chest x-ray may be used for routine follow-up but chest CT is preferred in the presence of thoracic symptoms.
⁶Patients with clinical stage II-A/II-B nonseminoma who undergo primary RPLND and are found to have pN0 disease (no tumor or teratoma, pathologic Stage I) should revert to the surveillance schedule for low-risk NSGCT with the exception that only 1 CT scan is needed postoperatively around month 4 (Table 5).
⁷This schedule assumes a complete resection has taken place.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIOTHERAPY FOR PURE TESTICULAR SEMINOMA

General Principles
• Modern radiotherapy involves smaller fields and lower doses than were used in the past. References are provided to support current recommended management.
• Risk-adapted management using tumor size >4 cm and rete testis invasion for stage I seminoma is discouraged. This is based on a validation study in 2010, which revealed that tumor size >4 cm and rete testis invasion were not predictors of relapse.1,2
• Linear accelerators with >6 MV photons should be used when possible.
• The mean dose (Dmean) and dose delivered to 50% of the volume (D50%) of the kidneys, liver, and bowel are lower with CT-based anteroposterior-posteroanterior (AP-PA) three-dimensional conformal radiation therapy (3D-CRT) than intensity-modulated radiation therapy (IMRT).3 As a result, the risk of second cancers arising in the kidneys, liver, or bowel may be lower with 3D-CRT than IMRT, and IMRT is not recommended. 4
• Timing of Radiotherapy:
  › Radiotherapy should start once the orchiectomy wound has fully healed.
  › Patients should be treated 5 days per week.
  › Patients who miss a fraction should be treated to the same total dose and with the same fraction size, extending the overall treatment time slightly.
• Antiemetic medication significantly improves nausea. See the NCCN Guidelines for Antiemesis. Antiemetic prophylaxis is encouraged at least two hours prior to each treatment, and some cases may require more frequent dosing.

Preparation for Radiotherapy
• A discussion of semen analysis and sperm banking prior to orchiectomy is recommended in patients who wish to preserve fertility.5,6 If sperm banking is desired, it should be performed prior to imaging and the delivery of adjuvant therapy.

Treatment Planning Principles
• A non-contrast CT simulation should be performed with the patient supine, arms at his sides, in the treatment position.
  › Immobilization with a cast may be used to improve the reproducibility of patient setup.
  › All patients, with the exception of those who have undergone bilateral orchiectomy, should be treated with a scrotal shield. The legs should be separated by a rolled towel of approximately the same diameter as the scrotal shield and its stand.
PRINCIPLES OF RADIOTHERAPY FOR PURE TESTICULAR SEMINOMA

**Stage I**

- Dose: For stages IA, IB, and IS, a total dose of 20.0 Gy (midplane) in 10 fractions. Daily 2.0-Gy is recommended for the minority of patients who prefer adjuvant treatment, realizing that there is a high likelihood of salvage should a relapse occur during surveillance.9

- Para-aortic (PA)-Strip Fields10 - Field Arrangement:
  - In patients with no history of pelvic or scrotal surgery, para-aortic strip irradiation may be delivered with opposed AP-PA fields. The weights of the fields may be equal.
  - Recent nodal mapping studies suggest that fields should target the retroperitoneal lymph nodes but not necessarily the ipsilateral renal hilar nodes (see Lateral borders).11,12
  - Superior and inferior borders: Borders may be determined by bony anatomy.
    - The superior border should be placed at the bottom of vertebral body T-11.13
    - The inferior border should be placed at the inferior border of vertebral body L-5.10,14
  - Lateral borders:
    - Conventionally, PA-strip fields are approximately 10 cm wide, encompassing the tips of the transverse processes of the PA vertebrae.
    - The location of the kidneys within the PA-strip fields varies from patient to patient.
      - For patients whose kidneys are relatively medial, small renal blocks may be added at the level of T-12. The right and left kidney D50% should be ≤8 Gy (ie, no more than 50% of each kidney can receive 8 Gy or higher).3 If only one kidney is present, the kidney D15% should be ≤20 Gy (ie, no more than 15% of the volume of the kidney can receive 20 Gy or higher).3
      - An alternative 3D-CRT planning technique is to base the lateral borders on vascular structures on a treatment planning CT scan without contrast. The aorta and inferior vena cava may be contoured on the CT scan; one should allow a 1.2-1.9-cm margin on the aorta and inferior vena cava to include the para-aortic, paracaval, interaortocaval, and preaortic nodes in the clinical target volume.11,15 The planning target volume is then established by uniformly expanding the clinical target volume by 0.5 cm in all directions to account for treatment setup errors.16 A uniform 0.7 cm margin should be provided on the planning target volume to the block edge to take beam penumbra into account (Figure 1, see TEST-C 4 of 5).3

**Special Considerations:**

- Ipsilateral pelvic surgery (eg, inguinal herniorrhaphy or orchiopexy) may alter the lymphatic drainage of the testis. As a result, irradiation of the ipsilateral iliac and inguinal lymph nodes, including the surgical scar from prior surgery, has been advocated even in stage I patients.12,17 Given the large volume of tissue that would be irradiated and the resulting increased risks of late effects, other management approaches are recommended for these patients.

For Stage IIA, IIB, see TEST-C 3 of 5
For References, see TEST-C 5 of 5
PRINCIPLES OF RADIOTHERAPY FOR PURE TESTICULAR SEMINOMA

Stage IIA-IIB

- Patients should not receive primary RT if they have a horseshoe (pelvic) kidney, inflammatory bowel disease, or a history of RT.
- For clinical stage IIA-B patients, treatment is delivered in two consecutive AP-PA phases (modified dog-leg fields and cone down). There is no break between the 2 phases.
- Modified Dog-Leg Fields:
  - Dose: The initial phase consists of treatment of modified dog-leg fields to 20.0 Gy (midplane) in 10 fractions; daily 2.0-Gy.
  - Target: The fields should include the retroperitoneal and proximal ipsilateral iliac lymph nodes.
    - Modified dog-leg fields as described by Classen et al are preferred.
    - Care should be taken to ensure coverage of the ipsilateral common, external, and proximal internal iliac lymph nodes down to the top of the acetabulum.
    - The fields can be set up using bony landmarks or by contouring the vascular structures, as for stage I.
      - The superior border should be placed at the bottom of vertebral body T-11.
      - The inferior border should be placed at the top of the acetabulum.
      - The medial border for the lower aspect of the modified dog-leg fields extends from the tip of the contralateral transverse process of the fifth lumbar vertebra toward the medial border of the ipsilateral obturator foramen.
      - The lateral border for the lower aspect of the modified dog-leg fields is defined by a line from the tip of the ipsilateral transverse process of the fifth lumbar vertebra to the superolateral border of the ipsilateral acetabulum.
      - Preferably, one should contour the aorta and inferior vena cava from the bottom of the T-11 vertebra inferiorly and ipsilateral iliac arteries and veins down to the top of the acetabulum. One should provide a 1.2- to 1.9-cm margin on these vascular structures for the clinical target volume. The planning target volume is then established by uniformly expanding the clinical target volume by 0.5 cm in all directions to account for treatment setup errors. A uniform 0.7 cm margin should be provided on the planning target volume to the block edge to take beam penumbra into account (Figure 2, see TEST-C 4 of 5).
      - It is not necessary to include the ipsilateral inguinal nodes or the inguinal scar in the AP-PA fields unless the patient has a history of ipsilateral pelvic surgery (e.g., inguinal herniorrhaphy or orchiopexy).
  - Cone Down:
    - Dose: The second phase (cone down) of the radiotherapy consists of daily 2-Gy fractions to a cumulative total dose of approximately 30 Gy for stage IIA and 36 Gy for stage IIB.
    - Target: The nodal mass (gross tumor volume) must be contoured. A uniform, 2-cm margin from the gross tumor volume to block edge should be provided for the AP-PA cone down fields (Figure 3, see TEST-C 4 of 5).
PRINCIPLES OF RADIOTHERAPY FOR PURE TESTICULAR SEMINOMA

Figure 1

Figure 2

Figure 3

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIOTHERAPY FOR PURE TESTICULAR SEMINOMA

References

### RISK CLASSIFICATION FOR ADVANCED DISEASE (post-orchiectomy)

<table>
<thead>
<tr>
<th>Risk Status</th>
<th>Nonseminoma</th>
<th>Seminoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good Risk</td>
<td>Testicular or retroperitoneal primary tumor and No nonpulmonary visceral metastases and Post-orchiectomy markers- all of: AFP &lt; 1,000 ng/mL hCG &lt; 5,000 iu/L LDH &lt; 1.5 x upper limit of normal</td>
<td>Any primary site and No nonpulmonary visceral metastases and Normal AFP Any hCG Any LDH</td>
</tr>
<tr>
<td>Intermediate Risk</td>
<td>Testicular or retroperitoneal primary tumor and No nonpulmonary visceral metastases and Post-orchiectomy markers- any of: AFP 1,000–10,000 ng/mL hCG 5,000–50,000 iu/L LDH 1.5–10 x upper limit of normal</td>
<td>Any primary site and Nonpulmonary visceral metastases and Normal AFP Any hCG Any LDH</td>
</tr>
<tr>
<td>Poor Risk</td>
<td>Mediastinal primary tumor or Nonpulmonary visceral metastases or Post-orchiectomy markers- any of: AFP &gt; 10,000 ng/mL hCG &gt; 50,000 iu/L LDH &gt; 10 x upper limit of normal</td>
<td>No patients classified as poor prognosis</td>
</tr>
</tbody>
</table>


1Markers used for risk classification are post-orchiectomy.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRIMARY CHEMOTHERAPY REGIMENS
FOR GERM CELL TUMORS

**EP**
Etoposide 100 mg/m² IV on Days 1–5
Cisplatin 20 mg/m² IV on Days 1–5
Repeat every 21 days¹

**BEP**
Etoposide 100 mg/m² IV on Days 1–5
Cisplatin 20 mg/m² IV on Days 1–5
Bleomycin 30 units IV weekly on Days 1, 8, and 15 or Days 2, 9, and 16
Repeat every 21 days²

**VIP**
Etoposide 75 mg/m² IV on Days 1–5
Mesna 120 mg/m² slow IV Push before ifosfamide on Day 1, then
Mesna 1200 mg/m² IV Continuous Infusion on Days 1–5
Ifosfamide 1200 mg/m² on Days 1–5
Cisplatin 20 mg/m² IV on Days 1–5
Repeat every 21 days³

## SECOND-LINE CHEMOTHERAPY REGIMENS FOR METASTATIC GERM CELL TUMORS

### Conventional-Dose Chemotherapy Regimens

**VeIP**
- Vinblastine 0.11 mg/kg IV Push on Days 1–2
- Mesna 400 mg/m^2^ IV every 8 hours on Days 1–5
- Ifosfamide 1200 mg/m^2^ IV on Days 1–5
- Cisplatin 20 mg/m^2^ IV on Days 1–5
- Repeat every 21 days

**TIP**
- Paclitaxel 250 mg/m^2^ IV on Day 1
- Ifosfamide 1500 mg/m^2^ IV on Days 2–5
- Mesna 500 mg/m^2^ IV before ifosfamide, and then 4 and 8 hours after each ifosfamide dose on Days 2–5
- Cisplatin 25 mg/m^2^ IV on Days 2–5
- Repeat every 21 days

### High-Dose Chemotherapy Regimens

**Carboplatin 700 mg/m^2^ (body surface area) IV**
- Etoposide 750 mg/m^2^ IV
- Administer 5, 4, and 3 days before peripheral blood stem cell infusion for 2 cycles

**Paclitaxel 200 mg/m^2^ IV over 24 hours on Day 1**
- Ifosfamide 2000 mg/m^2^ over 4 hours with mesna protection on Days 2–4
- Repeat every 14 days for 2 cycles followed by
- Carboplatin AUC 7–8 IV over 60 minutes Days 1–3
- Etoposide 400 mg/m^2^ IV Days 1–3
- Administer with peripheral blood stem cell support at 14- to 21-day intervals for 3 cycles

---

SUBSEQUENT CHEMOTHERAPY REGIMENS FOR METASTATIC GERM CELL TUMORS

**Palliative Chemotherapy Regimens**

- Gemcitabine/oxaliplatin
- Gemcitabine/paclitaxel
- Gemcitabine/paclitaxel/oxaliplatin
- Etoposide (oral)

*See references below for dosing.

**Etoposide (oral)**

**Gemcitabine/oxaliplatin**

**Paclitaxel/gemcitabine**

**Gemcitabine/oxaliplatin/paclitaxel**

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF SURGERY FOR GERM CELL TUMORS

- RPLND is the standard approach to the surgical management of NSGCTs in both the primary and post-chemotherapy setting.

- A template dissection or a nerve-sparing approach to minimize the risk of ejaculatory disorders should be considered in patients undergoing primary RPLND for stage I nonseminoma.

- The “split and roll” technique in which lumbar vessels are identified and sequentially ligated allows resection of all lymphatic tissue around and behind the great vessels (ie, aorta, IVC) and minimizes the risk of an in-field recurrence.

**Post-Chemotherapy Setting**

- Referral to high-volume centers should be considered for surgical resection of masses post-chemotherapy.

- Completeness of resection is an independent and consistent predictive variable of clinical outcome. In post-chemotherapy RPLND, surgical margins should not be compromised in an attempt to preserve ejaculation. Additional procedures and resection of adjacent structures may be required.

- Post-chemotherapy RPLND is indicated in metastatic NSGCT patients with a residual retroperitoneal mass following systemic chemotherapy and normalized post-chemotherapy serum tumor markers.

- A full bilateral template RPLND should be performed in all patients undergoing RPLND in the post-chemotherapy setting, with the boundaries of dissection being the renal hilar vessels (superiorly), ureters (laterally), and the common iliac arteries (inferiorly).
Table 1

American Joint Committee on Cancer (AJCC)
TNM Staging System for Testis Cancer (7th ed., 2010)

Primary Tumor (T)*

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pTX</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>pT0</td>
<td>No evidence of primary tumor (e.g. histologic scar in testis)</td>
</tr>
<tr>
<td>pTis</td>
<td>Intratubular germ cell neoplasia (carcinoma in situ)</td>
</tr>
<tr>
<td>pT1</td>
<td>Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis</td>
</tr>
<tr>
<td>pT2</td>
<td>Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis</td>
</tr>
<tr>
<td>pT3</td>
<td>Tumor invades the spermatic cord with or without vascular/lymphatic invasion</td>
</tr>
<tr>
<td>pT4</td>
<td>Tumor invades the scrotum with or without vascular/lymphatic invasion</td>
</tr>
</tbody>
</table>

*Note: Except for pTis and pT4, extent of primary tumor is classified by radical orchiectomy. TX may be used for other categories in the absence of radical orchiectomy.

Regional Lymph Nodes (N)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td>N2</td>
<td>Metastasis with a lymph node mass, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension</td>
</tr>
<tr>
<td>N3</td>
<td>Metastasis with a lymph node mass more than 5 cm in greatest dimension</td>
</tr>
</tbody>
</table>

Pathologic (pN)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pNX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>pN0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>pN1</td>
<td>Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to five nodes positive, none more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td>pN2</td>
<td>Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than five nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor</td>
</tr>
<tr>
<td>pN3</td>
<td>Metastasis with a lymph node mass more than 5 cm in greatest dimension</td>
</tr>
</tbody>
</table>

Distant Metastasis (M)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>M1a</td>
<td>Nonregional nodal or pulmonary metastasis</td>
</tr>
<tr>
<td>M1b</td>
<td>Distant metastasis other than to nonregional lymph nodes and lung</td>
</tr>
</tbody>
</table>

*Note: Except for pTis and pT4, extent of primary tumor is classified by radical orchiectomy. TX may be used for other categories in the absence of radical orchiectomy.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
### Table 1 (continued)

**American Joint Committee on Cancer (AJCC)**  
**TNM Staging System for Testis Cancer (7th ed., 2010)**

<table>
<thead>
<tr>
<th>Group</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>S (Serum Tumor Markers)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>pTis</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td>Stage I</td>
<td>pT1-4</td>
<td>N0</td>
<td>M0</td>
<td>SX</td>
</tr>
<tr>
<td>Stage IA</td>
<td>pT1</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>pT2</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td></td>
<td>PT3</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td></td>
<td>PT4</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td>Stage IS</td>
<td>Any pT/TX</td>
<td>N0</td>
<td>M0</td>
<td>S1-3</td>
</tr>
<tr>
<td>Stage II</td>
<td>Any pT/Tx</td>
<td>N1-3</td>
<td>M0</td>
<td>SX</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>Any pT/TX</td>
<td>N1</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>N1</td>
<td>M0</td>
<td>S1</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>Any pT/TX</td>
<td>N2</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>N2</td>
<td>M0</td>
<td>S1</td>
</tr>
<tr>
<td>Stage IIC</td>
<td>Any pT/TX</td>
<td>N3</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>N3</td>
<td>M0</td>
<td>S1</td>
</tr>
<tr>
<td>Stage III</td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1</td>
<td>SX</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1a</td>
<td>S0</td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1a</td>
<td>S1</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>Any pT/TX</td>
<td>N1-3</td>
<td>M0</td>
<td>S2</td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1a</td>
<td>S2</td>
</tr>
<tr>
<td>Stage IIIC</td>
<td>Any pT/TX</td>
<td>N1-3</td>
<td>M0</td>
<td>S3</td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1a</td>
<td>S3</td>
</tr>
<tr>
<td></td>
<td>Any pT/Tx</td>
<td>Any N</td>
<td>M1b</td>
<td>Any S</td>
</tr>
</tbody>
</table>

### Serum Tumor Markers (S)

- **SX**: Marker studies not available or not performed
- **SO**: Marker study levels within normal limits
- **S1**: 
  - LDH < 1.5 x N*  
  - hCG (mIU/mL) < 5,000  
  - AFP (ng/ml) < 1,000
- **S2**: 
  - LDH 1.5-10 x N  
  - hCG (mIU/mL) 5,000-50,000  
  - AFP (ng/ml) 1,000-10,000
- **S3**: 
  - LDH > 10 x N  
  - hCG (mIU/mL) > 50,000  
  - AFP (ng/ml) > 10,000

*N indicates the upper limit of normal for the LDH assay.

---

**Note**: All recommendations are category 2A unless otherwise indicated.  
NCCL Guidelines Index  
Testicular Cancer TOC  
Discussion

---

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ....................................................................................................................... 2

Literature Search Criteria and Guidelines Update Methodology ........... 2

Clinical Presentation ................................................................................................. 3

Diagnosis and Workup and Risk Assessment ......................................................... 3

Pure Seminoma ........................................................................................................ 4

Pure Seminoma Stages IA and IB ................................................................. 4

Pure Seminoma Stage IS .................................................................................. 7

Pure Seminoma Stages IIA and IIB ................................................................. 7

Pure Seminoma Stages IIC and III ................................................................. 8

Nonseminoma ......................................................................................................... 9

Nonseminoma Stage IA ...................................................................................... 10

Nonseminoma Stage IB ...................................................................................... 10

Nonseminoma Stage IS ..................................................................................... 11

Primary Treatment of Nonseminoma Stage IS ............................................. 11

Nonseminoma Stage IIA ..................................................................................... 11

Nonseminoma Stage IIB ..................................................................................... 12

Advanced Metastatic Nonseminoma .............................................................. 13

Second-Line Therapy for Metastatic Germ Cell Tumors ......................... 14

References .......................................................................................................... 16
Overview

An estimated 8,430 new cases of testicular cancer will be diagnosed in the United States in 2015. Germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes. These tumors also occur occasionally in extragonadal primary sites, but they are still managed the same as testicular GCTs. GCTs are relatively uncommon tumors and account for 1% of all male tumors. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past two decades.

Several risk factors for GCT development have been identified, including prior history of a GCT, positive family history, cryptorchidism, testicular dysgenesis, and Klinefelter’s syndrome.

GCTs are classified as seminoma or nonseminoma. Nonseminomatous tumors often include multiple cell types, including embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Teratomas are considered to be either mature or immature depending on whether adult-type differential cell types or partial somatic differentiation, similar to that present in the fetus, is found. Rarely, a teratoma histologically resembles a somatic cancer, such as sarcoma or adenocarcinoma, and is then referred to as a teratoma with malignant transformation.

The serum tumor markers alpha-fetoprotein (AFP), lactate dehydrogenase (LDH), and beta-human chorionic gonadotropin (beta-hCG) are critical in diagnosing the GCTs, determining prognosis, and assessing treatment outcome.

Serum tumor markers should be determined before and after treatment and throughout the follow-up period. Serum tumor markers are very useful for monitoring all stages of nonseminomas. Serum markers are also useful in monitoring metastatic seminomas, because elevated marker levels are the early signs of relapse.

LDH is a less specific marker compared to AFP and hCG. AFP is a serum tumor marker produced by nonseminomatous cells (ie, embryonal carcinoma, yolk-sac tumor) and may be seen at any stage. The approximate half-life of AFP is 5 to 7 days. A nonseminoma, therefore, is associated with elevated serum concentrations of AFP. When patients with a histologically “pure” testicular seminoma have an elevated level of AFP, it is generally assumed that an undetected focus of nonseminoma is present. An elevated serum concentration of beta-hCG, which has a half-life of approximately 1 to 3 days, may also be present with seminomatous and nonseminomatous tumors. The elevations of beta-hCG need to be interpreted with caution as hypogonadism and marijuana use may cause benign serum elevations of beta-HCG.

Nonseminoma is the more clinically aggressive tumor. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. Therefore, the diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP.

The 5-year survival for testis cancer is 98%. A delay in diagnosis correlates with a higher stage at presentation. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Testicular Cancer, an electronic search of the PubMed database was performed...
Diagnosis and Workup and Risk Assessment

Imaging and Blood Tests
If an intratesticular mass is identified, complete blood count, creatinine, electrolytes, and liver enzymes should be obtained.

Testicular ultrasound serves to confirm the presence of a testicular mass and to explore the contralateral testis. It is sensitive and has an important role in determining whether a mass is intra- or extratesticular.

Further evaluation includes measurement of the serum tumor markers, and a chest x-ray. Serum tumor markers are critical in the assignment of prognosis and management during treatment as well. Serum tumor markers are prognostic factors and contribute to diagnosis and staging. Markers are assessed before orchiectomy and repeated after orchiectomy. Elevated values of beta-hCG, LDH, or AFP should be followed up with repeated tests to allow precise staging.

Biopsy may also be considered if a suspicious intratesticular abnormality, such as a hypoechoic mass or macrocalcification, is identified on ultrasound. In contrast, if microcalcifications without any other abnormality can be observed, testicular biopsy is not necessary.

In patients of reproductive age, sperm banking must be discussed. It must be discussed with the patients before undergoing any therapeutic intervention that may compromise fertility, including surgery, radiation therapy, and chemotherapy. If sperm banking is desired, it may be performed either before or after orchiectomy but certainly prior to subsequent therapy.
**Primary Treatment**

Inguinal orchiectomy is considered the primary treatment for most patients who present with a suspicious testicular mass. An open inguinal biopsy of the contralateral testis is not routinely performed, but can be considered when a cryptorchid testis or marked atrophy is present. The extent of primary tumor is classified after orchiectomy, and therefore pathologic (p) stage is assigned to the primary tumor (T).

Further management is dictated by histology, a diagnosis of pure seminoma or non-seminoma (includes mixed seminoma tumors and seminoma histology with elevated AFP), and stage. Though rare, when a patient presents with rapidly increasing beta-hCG, symptoms related to disseminated disease and a testicular mass, chemotherapy can be initiated immediately without waiting for a biopsy diagnosis.

**Staging**

The TNM staging is based on post-orchiectomy value of beta-HCG, LDH, and AFP values. To assess for metastatic disease, it is important to obtain the half-life kinetics of serum tumor markers after orchiectomy; determine the status of retroperitoneal lymph nodes; determine the presence of lung metastasis; and determine the presence of brain or bone metastasis if suspicious clinical symptoms are present.

**Risk Classification for Advanced Disease**

In 1997, the International Germ Cell Cancer Consensus Group (IGCCCG) defined a prognostic factor-based classification system based on identification of some clinically independent prognostic features such as extent of disease and levels of serum tumor markers post-orchiectomy. Post-orchiectomy markers are utilized to classify the patient according to the IGCCCG risk classification. This classification categorizes patients with pure seminoma and non-seminoma GCT into good-, intermediate-, or poor-risk groups.

Definition of stage and risk classification is done according to the American Joint Committee on Cancer (AJCC) and IGCCCG classification.

**Pure Seminoma**

If a GCT is found, an abdominopelvic CT scan is performed. Abdominopelvic CT scanning is used to assess the retroperitoneal nodes.

A chest CT is indicated if the abdominopelvic CT shows retroperitoneal adenopathy or the chest x-ray shows abnormal results. A chest CT scan is a sensitive way to evaluate the thorax and mediastinal nodes.

The NCCN Panel Members recommend a brain MRI or bone scan, only if there is suspicion of metastases to these organs.

Elevated values of beta-HCG, LDH, or AFP should be followed with repeated tests. Serum concentrations of beta-hCG and LDH may be elevated in patients with seminoma. An elevated AFP level indicates nonseminoma, and the patient should be managed accordingly. Initial management of pure seminoma involves a radical inguinal orchiectomy. Orchiectomy is both diagnostic and therapeutic. Patients with seminoma arising from an extragonadal site, such as the mediastinum, are treated with standard chemotherapy regimens according to risk status.

**Pure Seminoma Stages IA and IB**

Primary Treatment for Pure Seminoma Stages IA and IB

Most patients with stage I seminoma are cured by orchiectomy alone. A small percentage of patients relapse. To prevent relapse in patients...
with stages IA and IB pure seminoma, the standard management options after initial orchiectomy include active surveillance, radiotherapy, or chemotherapy with 1 or 2 cycles of carboplatin. The disease-specific survival for stage I disease is 99% irrespective of the management strategy used.\(^{25}\)

**Surveillance:** A number of prospective non-randomized studies of surveillance have been conducted.\(^{26-29}\) The relapse rate seen in these studies is 15% to 20% at 5 years, and most of the relapses are first detected in infra-diaphragmatic lymph nodes.\(^{27-29}\) Some studies report tumor size greater than 4 cm and rete testis invasion as a risk factor in predicting relapse in patients.\(^{28,30,31}\) A validation study by Chung et al revealed that tumor size >4 cm and rete testis invasion were not predictors of relapse.\(^{32,33}\) Therefore, the NCCN Panel Members discourage risk-adapted management using tumor size >4 cm and rete testis invasion for stage I pure seminoma. A retrospective study analyzed a total of 2,483 patients with clinical stage I GCT managed with active surveillance. The analyses showed that 173 of 1,344 (13%) patients with stage 1 seminoma relapsed. Median time to relapse was 14 months (range, 2–84 months). Ninety two percent of the recurrences were observed within 3 years. The overall five-year disease-specific survival was 99.0%.\(^{34,35}\) Surveillance is listed as the preferred option (category 1) for patients with pT1-pT3 tumors by the NCCN Testicular Cancer Panel.

If surveillance is not applicable, alternatives are either adjuvant carboplatin or adjuvant radiotherapy as described below. Each approach has distinct advantages and disadvantages. The physicians should discuss these with the patients and their families and pick the best approach on a case-by-case basis.

**Adjuvant Therapy:** Oliver et al reported on the results of a trial that randomized 1,477 patients with stage 1 testicular cancer to undergo either radiotherapy or one injection of carboplatin.\(^{36}\) In the study, carboplatin (area under the curve [AUC] X 7) was administered intravenously. The dose was calculated by the formula 7 X (glomerular filtration rate [GFR, mL/min] + 25 mg). With a median follow-up of 4 years, the relapse-free survival rates for both groups were similar.\(^{36}\) Late relapses and secondary GCTs can occur beyond 5 and 10 years. Therefore, the investigators continued to follow these patients. The updated results reported non-inferiority of single-dose carboplatin versus radiation therapy.\(^{37}\) In an intent-to-treat analysis, the relapse-free rates at 5 years were 94.7% for the carboplatin arm and 96% for the radiotherapy arm (hazard ratio, 1.25; \(P = 0.37\)). There were 2 cases of contralateral GCTs on carboplatin versus 15 on radiation therapy with a hazard ratio of 0.22; the contralateral GCT-free rates at 5 years were 99.8% and 98.8%, respectively. The authors concluded that a single dose of carboplatin is less toxic and as effective in preventing disease recurrence as adjuvant radiotherapy in men with stage I pure seminoma after orchiectomy.\(^{37}\) Two courses of adjuvant carboplatin have also been reported to reduce the relapse rate.\(^{38}\)

The NCCN Panel does not prefer the routine use of adjuvant therapy for stage I seminoma patients as the risk of recurrence is low compared to the potential harms of adjuvant therapy. It has been suggested that radiotherapy might increase the risk of a subsequent cardiac event,\(^{39}\) but recent other analyses have not confirmed this risk.\(^{40}\)

Another study found that moderate-dose infradiaphragmatic RT for stage I seminoma was associated with increased risks of second cancers (non-testicular germ cell) to organs in the radiation field. As with RT, platinum-based chemotherapy has been associated with an increased risk of cancer and heart disease.
However, if adjuvant chemotherapy is opted, the NCCN Testicular Cancer Panel recommends carboplatin AUC X 7 for either 1 or 2 cycles as a category 2A recommendation for patients with stages IA and IB pure seminoma.

If RT is delivered, the NCCN Panel recommends a total dose of 20.0 Gy (midplane) in 10 daily 2.0 Gy fractions,\(^{41}\) given to an infradiaphragmatic area, including para-aortic lymph nodes; in special circumstances, it may include the ipsilateral ilioinguinal nodes.\(^{42-45}\) Patients for whom RT is generally not given include those at higher risk for morbidity from radiation therapy such as those with a history of pelvic surgery. Prophylaxis to the mediastinum is not provided, because relapse rarely occurs at this site.

For patients with stages IA and IB pure seminoma, adjuvant radiation therapy to include para-aortic nodes is also a category 2A recommendation in the NCCN Guidelines for Testicular Cancer, though active surveillance is preferred (see Principles of Radiotherapy for Pure Testicular Seminoma in the algorithm).

**Follow-up After Primary Treatment for Pure Seminoma Stages IA and IB**

For follow-up, it is important to distinguish the different risk of recurrence associated with each treatment modality (surveillance vs. adjuvant therapy). An analysis of more than 5,000 stage I seminoma patients from various trials showed that independent of the treatment modality, the risk of recurrence is highest in the first 2 years and decreases after that.\(^{46}\) The NCCN Panel recommends performing testicular ultrasound in case other recommended tests are equivocal.

**Follow-up During Active Surveillance:** The NCCN Panel has provided updated guidelines for follow-up of patients with stage 1 seminoma on active surveillance (see TEST-A, page 1 of 2). Follow-up for patients on surveillance includes a history and physical, with measurement of post-orchiectomy serum tumor markers (AFP, beta-HCG, and LDH), performed every 3 to 6 months for the first year, every 6 to 12 months for years 2 to 3, and annually thereafter.\(^{47-49}\)

There is controversy regarding how many imaging studies must be performed in patients on active surveillance. The NCCN Panel recommends abdominal/pelvic CT every 3, 6, and 12 months for the first year, every 6 to 12 months for years 2 and 3, and then every 12 to 24 months for years 4 and 5.

No initial relapses in the lung have been reported in studies of patients with stage I seminoma managed by active surveillance; therefore, according to the NCCN Panel routine chest imaging during surveillance is only indicated for patients with thoracic symptoms.

A clinical trial in the United Kingdom, entitled TRISST (MRC TE24/TRial of Imaging and Schedule in Seminoma Testis), is currently studying whether a reduced CT schedule or MRI could be used as a safe and effective alternative to standard CT-based surveillance in the management of stage I seminoma.\(^{50}\)

**Follow-up After Adjuvant Treatment (carboplatin or RT):** The risk of recurrence 5 years after adjuvant treatment is <0.3% annually.\(^{46}\) Follow-up of patients treated with adjuvant therapy (carboplatin or RT) includes a history and physical, with measurement of post-orchiectomy serum tumor markers (AFP, beta-HCG, and LDH) performed every 6 to 12 months for the first 2 years and annually thereafter.
Patients treated with para-aortic radiation therapy have a slightly higher rate of pelvic relapse compared with those treated with “dog-leg” RT.\textsuperscript{43,46,51,52} In a meta-analysis of 2,466 patients, Mead et al reported that recurrence rarely occurred after more than 3 years from treatment with either RT or carboplatin.\textsuperscript{25} Relapse occurred after 3 years only in 4 out of the 2,466 patients (0.2%).\textsuperscript{25} Since the rate of recurrence for patients treated with chemotherapy and radiation therapy beyond 3 years is very low, the NCCN Panel recommends performing abdominal and pelvic CT scans annually for 3 years in patients treated with radiotherapy or carboplatin. Chest x-rays should be obtained only when clinically indicated. Recurrences are treated according to the stage at relapse.\textsuperscript{25}

**Pure Seminoma Stage IS**

**Primary Treatment for Pure Seminoma Stage IS**

By the AJCC definition, stage IS requires persistent elevation of serum tumor markers (LDH, AFP, and beta-HCG) following orchiectomy. Stage IS pure seminoma is very uncommon and caution is warranted before intervention based on minimally elevated LDH or beta-HCG, as other causes may be responsible. Persistent elevation of serum markers is usually evidence of metastatic disease, which will show up radiographically if doubt exists in the diagnosis.

**Follow-up After Primary Radiation Treatment for Pure Seminoma Stage IS**

The NCCN Panel recommends repeating evaluation of serum markers and performing imaging studies to determine the extent of disease. If there is persistent elevation of markers, treatment with chemotherapy is similar to that of nonseminoma (see section on non-seminoma below).

**Pure Seminoma Stages IIA and IIB**

**Primary Treatment for Pure Seminoma Stages IIA**

Stage IIA is defined as metastatic disease to lymph nodes, with a lymph node mass measuring less than or equal to 2 cm in diameter in greatest dimension on CT scan, and stage IIB as disease measuring greater than 2 but less than 5 cm in maximum diameter.

RT has been the mainstay of treatment in stage IIA and IIB seminoma patients with low-volume disease.\textsuperscript{53-55} The NCCN Panel prefers RT over chemotherapy for patients with stage IIA. The relapse rates are moderate (5%–6% for stage IIA), and overall survival is almost 100%.\textsuperscript{53,55,56} The standard radiation field compared with stage I is extended from the para-aortic region to include an ipsilateral iliac field in two consecutive anteroposterior-posteroanterior phases without a break in between. The initial phase consists of radiation to modified dog-leg fields consisting of a dose of 20.0 Gy (midplane) in 10 daily 2.0 Gy fractions\textsuperscript{42} or 25.5 Gy in 15 daily 1.7 Gy fractions.\textsuperscript{57} The panel prefers modified dog-leg fields as described by Classen et al.\textsuperscript{53} For details on field arrangement, see *Principles of Radiotherapy for Pure Testicular Seminoma* in the algorithm.

The second phase (cone down) of radiotherapy consists of daily 2.0 Gy fractions to a cumulative total dose of approximately 30 Gy for stage IIA and 36 Gy for selected patients with non-bulky stage IIB disease.\textsuperscript{53} As with the management of stage I disease, prophylactic mediastinal radiation therapy is not indicated for stage II disease.\textsuperscript{58}

For stage IIB seminoma patients such as those with adenopathy measuring more than 3 cm,\textsuperscript{59} chemotherapy with 4 courses of etoposide and cisplatin (EP) or 3 cycles of bleomycin, etoposide, and cisplatin (BEP) is the preferred alternative to radiotherapy.\textsuperscript{56,60} For
patients with stage IIA disease, chemotherapy with 4 cycles of EP or 3 cycles of BEP is an option for patients with multiple positive nodes.

**Follow-up for Stages IIA and non-bulky IIB Pure Seminoma After Primary Treatment**

The recommended follow-up schedules after radiation therapy for patients with stage IIA and non-bulky IIB tumors include a history and physical with measurement of post-orchiectomy serum tumor markers (AFP, beta-HCG, and LDH), performed every 3 months for year 1 and then every 6 months for years 2 through 5.

Chest x-ray is recommended every 6 months for the first 2 years. An abdominal CT scan is recommended at 3 months, then at 6 and 12 months in year 1, and then annually for years 2 and 3 after radiotherapy and as clinically indicated thereafter.

The follow-up of stage II patients with bulky tumors treated with chemotherapy is similar to follow-up after chemotherapy for patients with stages II and III and is discussed in the section below on **Follow-up of Pure Seminoma Bulky Stage II and Stage III After Chemotherapy**.

**Pure Seminoma Stages IIC and III**

**Primary Treatment for Pure Seminoma Stages IIC and III**

Patients with stage IIC or III disease are those considered at either good or intermediate risk. All stage IIC and stage III seminoma is considered good-risk disease except for stage III disease with non-pulmonary visceral metastases (eg, bone, liver, brain), which is considered intermediate risk. Standard chemotherapy is used for both groups of patients. However, for patients with good risk, 3 cycles of BEP or 4 cycles of EP are recommended. In contrast, more intensive chemotherapy (ie, 4 cycles of BEP) is recommended for those with intermediate-risk disease. All these chemotherapy options are category 1 recommendations according to the NCCN Testicular Cancer Panel.

**Post-chemotherapy Management of Pure Seminoma Stages IIA, IIB, IIC, and III**

After chemotherapy, patients with stage IIA, IIB, IIC, and III are evaluated with serum tumor markers and a CT scan of the chest, abdomen, and pelvis. Patients are then classified according to the presence or absence of a residual mass and the status of serum tumor markers. Patients with normal markers and either no residual mass or residual mass of 3 cm or less need no further treatment. They should undergo surveillance as discussed in the section below, on **Follow-up for Pure Seminoma Bulky Stage II and Stage III After Chemotherapy**.

In cases of residual tumor >3 cm and marker levels that are normal, a PET scan is recommended to assess whether there is residual viable tumor. A PET scan has a high positive and negative predictive value with regard to the question of remaining disease in patients with residual masses after chemotherapy. To reduce the incidence of false-positive results, the PET scan is typically performed at least 6 weeks after completion of chemotherapy. Notably, granulomatous disease, such as sarcoid, is a source of false-positive results. The NCCN Panel recommends a PET scan in patients with seminoma, and a residual mass >3 cm and normal levels of markers, approximately 6 weeks after chemotherapy in order to decide whether to continue with surveillance or resume treatment.

If the PET scan is negative, no further treatment is needed; however, the patient should undergo follow-up as discussed in the section below, on **Follow-up of Pure Seminoma Bulky Stage II and Stage III After Chemotherapy**.
Since a positive PET scan is a strong indicator of residual active tumor, resection should be considered. Therefore, if technically feasible, retroperitoneal lymph node dissection (RPLND) may be considered (category 2A). The other option, if resection is not feasible, is second-line chemotherapy (category 2A). Cisplatin-based combination chemotherapy is used for second-line treatment. The regimens are four cycles of TIP (paclitaxel, ifosfamide, cisplatin) or four cycles of VeIP (vinblastine, ifosfamide, cisplatin).

According to the NCCN Guidelines, second-line therapy for seminoma and nonseminoma is similar. It is discussed below in Second-line Therapy for Metastatic Germ Cell Tumors. The follow-up of these patients is also described below.

**Follow-up of Pure Seminoma Bulky Stage II and Stage III After Chemotherapy**

The NCCN Panel-recommended follow-up schedules for patients with bulky stage II or stage III disease after treatment with chemotherapy and either no or ≤3 cm residual mass and normal tumor markers includes a history and physical and measurement of post-orchiectomy serum tumor markers every 2 months for the first year, every 3 months for the second year, every 6 months for the third and fourth years, and annually for year 5. An abdominal/pelvic CT scan is recommended at 3 and 6 months and then as clinically indicated. A PET scan may be performed as clinically indicated. Chest x-ray is recommended every 2 months during the first year, every 3 months during the second year, and annually during years 3 through 5. Chest CT is preferred over chest x-ray in patients with thoracic symptoms. Viable tumor cells have been found in tumors >3 cm even with a negative PET scan after chemotherapy treatment. The NCCN Panel notes that patients with PET-negative result and tumor residual mass measuring >3 cm after chemotherapy should undergo an abdominopelvic CT scan every 6 months for the first year and then annually for 5 years.

**Nonseminoma**

Similar to the workup for seminoma, if non-seminoma is found, CT of the abdomen and pelvis should be performed with chest imaging if needed. MRI of the brain and bone scan should be conducted in the case of clinical indicators (symptoms) of involvement. PET scanning does not contribute and routine use is not recommended for nonseminoma patients.

Elevated values of beta-HCG, LDH, or AFP should be followed up with repeated tests. Nonseminoma includes mixed seminoma tumors and seminoma histology with elevated AFP. Post-orchiectomy serum markers are important for TNM staging and to classify the patient with nonseminoma according to the IGCCCG risk classification into good-, intermediate-, and poor-risk groups.

In patients of reproductive age, sperm banking must be discussed. It must be discussed with the patients before undergoing any therapeutic intervention that may compromise fertility, including surgery, radiation therapy, or chemotherapy. If sperm banking is desired, it may be performed either before or after orchiectomy, but certainly prior to adjuvant therapy.

Stage-dependent treatment options after inguinal orchiectomy include surveillance, chemotherapy, and RPLND. Although the timing of the RPLND may vary, most patients with nonseminoma will undergo an RPLND for either diagnostic or therapeutic purposes at some point during treatment. The major morbidity associated with bilateral
dissection is retrograde ejaculation, resulting in infertility. Nerve dissection techniques preserve antegrade ejaculation in 90% of cases.™

**Nonseminoma Stage IA**

**Primary Treatment of Nonseminoma Stage IA**

According to the NCCN Testicular Cancer Panel, two management options exist for patients with stage IA disease after orchiectomy: 1) surveillance;™ and 2) nerve-sparing RPLND. The cure rate with either approach exceeds 95%. However, the high cure rate associated with surveillance depends on adherence to periodic follow-up examinations and subsequent chemotherapy for the 20% to 30% of patients who experience relapse. Surveillance is the preferred option for patients with stage 1A tumors by the NCCN Panel. Patients who choose surveillance should agree to be compliant for follow-up. When RPLND is performed, it should be done using a nerve-sparing technique.™ According to the NCCN Guidelines, the nerve-sparing RPLND is recommended within 4 weeks of a CT scan and within 7 to 10 days of repeat serum marker testing to ensure accurate presurgical staging.

**Management of Nonseminoma Stage IA After RPLND**

After RPLND, if the dissected lymph nodes are not involved with a tumor (pN0), no adjuvant chemotherapy is given. The patients should undergo surveillance. However, if the resected lymph nodes involve tumor, the decision whether to use adjuvant chemotherapy is based on the degree of nodal involvement. Surveillance is preferred over chemotherapy for patients with pN1 disease. Chemotherapy is preferred in patients with pN2 or pN3 disease. Surveillance is an option for patients with pN2 but is not an option for patients with pN3 disease. Recommended chemotherapy regimens include either EP or BEP. Two cycles of either regimen (EP or BEP) are recommended for patients with pN1 or pN2 disease.™ For patients with pN3 disease, longer courses of chemotherapy with 4 cycles of EP or 3 cycles of BEP is recommended.

**Follow-up for Nonseminoma Stage IA**

In the updated NCCN Guidelines, the long-term follow-up tests for stage IA patients electing primary surveillance, post-RPLND, or post-chemotherapy include serum marker assessment, chest x-ray, and an abdominal CT scan. The frequency of these tests is outlined in the algorithm on TEST-B page 1 of 3, entitled *Follow-up for Nonseminoma*.

**Nonseminoma Stage IB**

**Primary Treatment of Nonseminoma Stage IB**

After orchiectomy, either nerve-sparing RPLND or adjuvant chemotherapy is an option to reduce the risk of relapse in patients with stage IB disease. Several studies using two cycles of BEP as primary treatment for stage I nonseminoma patients have been reported with relapse-free survival in greater than 95% of patients.™ Based on these studies the NCCN Panel considers 1 to 2 cycles of BEP as primary chemotherapy as an option. Late consequences of cisplatin-based chemotherapy have been reported based on long-term follow-up of patients.™ A trial by Albers et al randomized stage I patients after orchiectomy to undergo unilateral RPLND (n = 191) or one adjuvant course of BEP (n = 191).™ After a median follow-up of 4.7 years, two relapses were reported in the group of patients treated with one course of adjuvant BEP and in 13 patients with relapse in the arm treated with RPLND (P = .0011). This study indicates that one course of BEP is active in patients and could be an option in patients unable to tolerate the toxicity of treatment. The comparator arm in this trial (unilateral RPLND) is not the standard treatment approach. Therefore, while the results of this...
study are promising, this merits further investigation comparing 1 cycle of BEP versus 2 cycles with longer follow-up.

Surveillance alone may be offered to selected patients with T2 disease (category 2B). Vascular invasion is a significant predictor of relapse when orchiectomy is followed by surveillance alone. Surveillance is generally not recommended for T2 disease with vascular invasion because of the 50% chance of relapse. Exceptions are made according to individual circumstances. When surveillance is opted in selected patients with T2 disease, both the patient and the physician must be compliant with follow-up recommendations.

**Management of Nonseminoma Stage 1B After Primary Treatment**

The adjuvant treatment following primary nerve-sparing RPLND for patients with IB is similar to that described for stage IA in the section above, on *Management of Nonseminoma Stage 1A After RPLND.*

In the updated NCCN Guidelines, the long-term routine follow-up tests for the select patients with T2 disease undergoing surveillance and for those who underwent chemotherapy include serum marker assessment, chest x-ray, and an abdominal/pelvic CT scan. The frequency of these tests varies depending on the adjuvant management strategy, and the frequency of the tests are outlined in the algorithm on TEST-B page 1 of 3 and 2 of 3, on *Follow-up for Nonseminoma.*

**Nonseminoma Stage IS**

Patients with stage IS disease exhibit a persistent elevation of serum tumor markers post-orchiectomy but no radiographic evidence of disease. The elevated levels of AFP and beta-HCG after orchiectomy must be interpreted with caution, as the reason for marker elevation might be other than disseminated nonseminoma such as hepatobiliary disease, marijuana use, and hypogonadism.

**Primary Treatment of Nonseminoma Stage IS**

The consensus recommendation of the NCCN Panel is that these patients be treated with standard chemotherapy with either 4 cycles of EP or 3 cycles of BEP. Both are NCCN category 1 and either regimen is preferable to initial RPLND because these patients nearly always have disseminated disease.\(^{113,114}\)

**Management of Stage 1S Nonseminoma Post-primary Treatment**

The management of patients with stage IS nonseminoma after primary treatment with chemotherapy is described in *Advanced Metastatic Nonseminoma,* below.

**Nonseminoma Stage IIA**

*Primary Treatment of Nonseminoma Stage IIA*  
Treatment for patients with stage IIA nonseminoma depends on post-orchiectomy serum tumor marker levels.

For patients with normal post-orchiectomy levels of AFP and HCG, the NCCN Panel considers either primary RPLND (category 2A) or chemotherapy (category 2B) as treatment options for stage IIA.\(^{115-119}\) The chemotherapy regimens include 4 cycles of EP or 3 cycles of BEP. Chemotherapy is considered particularly appropriate if the patient has multifocal disease.

For patients with persistently elevated AFP or HCG levels, the NCCN Panel recommends induction chemotherapy. The data supporting this come from 2 retrospective studies of patients with low-stage nonseminoma treated by RPLND.\(^ {120,121}\) The presence of elevated postorchiectomy AFP or HCG levels was associated with a high risk of relapse.\(^ {120,121}\)
Management after primary chemotherapy and RPLND is discussed in sections below.

Management After Primary Treatment of Nonseminoma Stage IIA
After primary chemotherapy, the subsequent management depends on marker levels and the residual mass on CT scan. Therefore, the patients must undergo a CT scan before treatment decisions. Lesions less than 1 cm on CT scan may represent false positives and must be interpreted with caution. The options listed by the NCCN Panel for managing stage IIA patients after primary chemotherapy include nerve-sparing bilateral RPLND or surveillance.

The NCCN Testicular Cancer Panel considers nerve-sparing bilateral RPLND a category 2A recommendation for patients with residual mass of 1 cm or greater and category 2B if the residual mass is less than 1 cm. A bilateral RPLND involves removal of lymphatic tissue between both ureters, spanning from the diaphragmatic crus to the bifurcation of the common iliac arteries. The rationale for this extended region of dissection is the greater likelihood of bilateral disease with greater tumor burden. Referral to high-volume centers must be considered for RPLND post-chemotherapy. Surveillance is an option for selected patients with negative markers or patients with residual mass less than 1 cm.

After primary nerve-sparing RPLND, the treatment options include either surveillance or chemotherapy. The treatment choice depends on the number of positive lymph nodes identified. For example, since RPLND is likely a curative procedure in patients with pathologic stage N0 (pN0), surveillance is the only option listed for this group. Surveillance and chemotherapy are options for patients with pN1 and pN2 disease. RPLND is a curative procedure in 60% to 90% of pN1 patients; therefore, the NCCN Panel prefers surveillance over chemotherapy for patients with pN1 disease. The risk of relapse in patients with pN2-pN3 disease is >50%. With 2 cycles of adjuvant cisplatin-based chemotherapy, the risk of relapse after RPLND is generally <1%. The NCCN Panel prefers 2 cycles of adjuvant chemotherapy for pN2 disease; and full course chemotherapy (not surveillance) is recommended for pN3 disease. Recommended adjuvant chemotherapy regimens for pN1 and pN2 consists of 2 cycles of BEP or 2 cycles of EP; resulting in a nearly 100% relapse-free survival rate. For pN3, the NCCN Panel recommends a longer chemotherapy course consisting of either 4 cycles of EP or 3 cycles of BEP.

If stage IIA patients have persistent marker elevation (ie, stage IIA, S1), the primary treatment is chemotherapy as described for good-risk nonseminoma in sections below.

Nonseminoma Stage IIB
Primary Treatment of Nonseminoma Stage IIB
Treatment for patients with stage IIB nonseminoma also depends on both post-orchiectomy tumor marker levels and radiographic findings. When tumor markers are negative, the CT findings determine the proper course of treatment. If abnormal radiographic findings are limited to sites within the lymphatic drainage in the retroperitoneum (ie, the landing zone), two management options are available. One option is to perform nerve-sparing RPLND and to consider adjuvant treatment as described for patients with stage IIA disease. The second option is to treat with primary chemotherapy with either 4 cycles of EP or 3 cycles of BEP, followed by nerve-sparing RPLND or surveillance. Both options of primary chemotherapy or primary RPLND are comparable options in terms of outcome, but side effects and toxicity
are different. The reported relapse-free survival with either approach is close to 98%. If metastatic disease (based on radiographic findings) is not confined to the lymphatic drainage (i.e., multifocal lymph node metastases outside the lymphatic drainage sites), chemotherapy is recommended with either 4 cycles of EP or 3 cycles of BEP, followed by nerve-sparing RPLND or surveillance.

For stage IIB patients with persistent marker elevation (stage IIB, S1), the primary treatment is chemotherapy as described for good-risk nonseminoma including stages IS, IIC, and IIIA in sections below (see section below). Initial RPLND is not recommended in this situation.

Management After Primary Treatment of Nonseminoma Stage IIB
The management of patients with stage IIB nonseminoma after primary treatment with either nerve-sparing bilateral RPLND or chemotherapy is similar to the management scheme post-primary outlined above for patients with stage IIA nonseminoma.

Advanced Metastatic Nonseminoma
The primary chemotherapy regimens of choice for patients with advanced disease depends on the IGCCCG risk classification. This classification categorizes patients as good, intermediate, or poor risk. Also, patients with an extragonadal primary site, whether retroperitoneal or mediastinal, are treated with initial chemotherapy.

Primary Treatment of Good-risk Nonseminoma
Based on the IGCCCG good-risk classification, this group includes patients with stages IS, IIA and IIB (with persistent marker elevation), IIC, and IIIA. Treatment for good-risk GCTs were designed to decrease toxicity while maintaining maximal efficacy. Randomized clinical trials showed that this can be achieved by either substituting etoposide for vinblastine or by eliminating or reducing the dose of bleomycin. Presently two regimens are recommended by the NCCN Testicular Cancer Panel: 4 cycles of EP or 3 cycles of BEP (both category 2A). Either regimen is well tolerated and cures approximately 90% of patients with good risk.

Primary Treatment of Intermediate-risk (stage IIB) Nonseminoma
For patients with intermediate risk, the cure rate is approximately 70% with standard therapy using 4 cycles of BEP. For patients with intermediate risk (stage IIB), 4 cycles of BEP is a category 2A recommendation by the NCCN Testicular Cancer Panel.

Primary Treatment of Poor-risk (stage IIC) Nonseminoma
In patients with poor-risk GCTs (stage IIC), between 20% and 30% of all patients with metastatic GCTs are not cured with conventional cisplatin therapy and less than one half experience a durable complete response to 4 cycles of BEP; therefore, treatment in a clinical trial is preferred. The NCCN Panel lists enrolling these patients in clinical trials as their preferred treatment option.

The standard chemotherapy regimen for poor-risk patients is 4 cycles of BEP. The regimen containing VIP (etoposide, ifosfamide, cisplatin) was compared to BEP and found to be more toxic, compared with BEP, but equally effective. Therefore, 4 cycles of VIP may be used for those who may not tolerate bleomycin.

Post-chemotherapy Management for Good-, Intermediate-, and Poor-risk Nonseminoma
At the conclusion of induction chemotherapy, CT scans of the abdomen and pelvis are indicated, along with serum tumor marker assays. PET scans for residual disease have limited predictive value.
If a complete response to chemotherapy is found by radiographic imaging, and the tumor markers are negative, the NCCN Panel lists management options depending on the original stage of the disease: surveillance (category 2B) if original stage was IS; or either surveillance (category 2A) or bilateral RPLND using nerve-sparing technique if possible (category 2B),77 if the original stage of disease was IIA, S1, IIB, S1, IIC, or IIIA.

If there is a partial response to chemotherapy or a residual mass is found and the serum tumor markers (AFP and beta-HCG) have normalized, then all sites of residual disease are resected.143-145 If only necrotic debris or mature teratoma is encountered, no further therapy is necessary and patients must be put under surveillance. If embryonal, yolk sac, choriocarcinoma, or seminoma elements are found in the residual mass, 2 cycles of conventionally dosed chemotherapy (EP, VelP, VIP, or TIP) are administered.

The recommended follow-up tests and their frequencies during surveillance, after chemotherapy or after bilateral RPLND, are outlined in the algorithm on page TEST-B 2 of 3, entitled Follow-up for Nonseminoma. After patients are rendered disease-free, standard surveillance is initiated.

Patients who experience an incomplete response to first-line therapy are treated with second-line therapy (see section below). The NCCN Testicular Cancer Panel prefers that patients with recurrent nonseminoma be treated at centers with expertise in the management of this disease in conjunction with best supportive care.

Second-Line Therapy for Metastatic Germ Cell Tumors

Patients who do not experience a durable complete response to first-line therapy or those who experience a recurrence can be divided into those with a favorable or unfavorable prognosis based on prognostic factors. Prognostic factors can be used in deciding whether a patient is a candidate for conventional dose therapy or high-dose therapy with stem cell support as a second-line option. To determine the prognosis at initial diagnosis, the IGCCCG classification is used. However, for patients with progressive or relapsed disease after first-line treatment, several prognostic models have been reported.146-148 Favorable prognostic factors to conventional dose second-line chemotherapy include a testicular primary site, prior complete response to first-line therapy, low levels of post-orchiectomy serum tumor markers, and low-volume disease.146 Standard second-line therapy includes conventional dose chemotherapy or high-dose chemotherapy. The conventional dose regimen includes cisplatin and ifosfamide combined with either vinblastine or paclitaxel.149

If the patient experiences an incomplete response or relapses after second-line conventional dose chemotherapy, the preferred third-line option, if the second-line therapy included conventional dose chemotherapy, would be high-dose chemotherapy or chemotherapy in the context of a clinical trial. A surgical salvage could be considered if the relapse is in a solitary resectable site.

Unfavorable prognostic features include incomplete response to first-line treatment, high levels of serum markers, high-volume disease, and presence of extratesticular primary tumor. Patients with a testicular primary site and rising post-orchiectomy serum tumor markers during first-line therapy are usually considered for high-dose programs. Chemotherapy options for patients with poor prognostic features
include chemotherapy in the context of a clinical trial; conventional-dose second-line therapy (with VeIP or TIP); and high-dose chemotherapy (category 2B). Alternatively, the patients may be put on palliative chemotherapy or salvage surgery if feasible.\textsuperscript{152,153} The high-dose regimens include high-dose carboplatin plus etoposide followed by autologous stem cell transplant\textsuperscript{147,154} or paclitaxel, and ifosfamide followed by high-dose carboplatin plus etoposide with stem cell support.\textsuperscript{155}

A late relapse (>2 years after completion of primary therapy) occurs in 2% to 3% of survivors.\textsuperscript{156-158} The NCCN Panel prefers surgical resection, if technically feasible.\textsuperscript{152,159,160} Conventional dose chemotherapy or high-dose chemotherapy are other options for patients with late relapses.

For patients with unfavorable prognosis and late relapses who do not experience complete response to second-line high-dose therapy, the disease is nearly always incurable; the only exception is the rare patient with elevated serum tumor markers and a solitary site of metastasis (usually retroperitoneal) that undergoes surgical resection.\textsuperscript{161} Other options are participation in a clinical trial or palliative chemotherapy.

**Palliative Therapy**
All patients with either persistent or recurrent disease should be considered for palliative chemotherapy or radiation therapy.

The palliative chemotherapy options for patients with intensively pretreated, cisplatin-resistant, or refractory GCT are combinations of gemcitabine with paclitaxel and/or oxaliplatin\textsuperscript{162-167} or oral etoposide.\textsuperscript{168}

The recommendation for gemcitabine and oxaliplatin (GEMOX) is based on data from phase II studies.\textsuperscript{162-164} These studies investigated the efficacy and the toxicity of GEMOX in patients with relapsed or cisplatin-refractory GCTs. The results showed that GEMOX is safe for patients with cisplatin-refractory testicular GCTs and may offer a chance of long-term survival.\textsuperscript{162-164}

Gemcitabine and paclitaxel is another option that has shown promising results in a phase II study,\textsuperscript{166} and long-term follow-up results with this combination show long-term disease-free survival in the rare patients who progressed after high-dose chemotherapy and had not received prior paclitaxel or gemcitabine.\textsuperscript{167}

A phase II study of patients with treatment-refractory germ-cell tumors found the combination of gemcitabine, oxaliplatin, and paclitaxel to be effective with acceptable toxicity.\textsuperscript{165} In a phase II study in patients who had previous treatment with cisplatin/etoposide combination regimens, high-dose etoposide and carboplatin with autologous bone marrow transplantation showed that single-agent oral etoposide was effective.\textsuperscript{168}

For palliative therapy, the NCCN Testicular Cancer Panel recommends GEMOX\textsuperscript{162-164}, gemcitabine with paclitaxel\textsuperscript{166,167}, gemcitabine with oxaliplatin and paclitaxel\textsuperscript{165}, or oral etoposide\textsuperscript{168} (all are category 2A recommendations).

**Treatment of Brain Metastases**
The prognosis of patients with brain metastasis is poor.\textsuperscript{169,170} Primary chemotherapy (using a cisplatin-based regimen) is indicated for patients in whom brain metastases are detected and there are data supporting use of radiation therapy with chemotherapy.\textsuperscript{170,171} If clinically indicated and feasible, surgical resection of the metastasis should also be performed.
References


12. U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd_key.html. Available at:


50. TRISST (MRC TE24) Trial of imaging and schedule in seminoma tests. Available at: http://www.ctu.mrc.ac.uk/our_research/research_areas/cancer/studies/trisst_mrc_te24/.


61. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and


116. Weissbach L, Bussar-Maatz R, Flechtnr H, et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ


